RÉSUMÉ
Objective :To observe therapeutic effect and safety of perindopril combined amlodipine (P+ A) and valsartan combined amlodipine (V+A) on hypertension .Methods :A total of 126 patients with hypertension treated in our hospital were enrolled.The patients were randomly and equally divided into V + A group and P+ A group ,both groups received corresponding treatment based on routine intervention for 12 weeks.Levels of systolic blood pressure (SBP) ,diastolic blood pressure (DBP) ,heart rate (HR) ,plasma nitric oxide (NO) ,endothelin (ET)-1 ,von Willebrand factor (vWF) ,serum cystatin C (CysC) and uric acid (SUA) before and after treatment ,therapeutic effect and incidence rate of adverse reac-tions were observed and compared between two groups .Results :Total effective rate of V+A group was significantly higher than that of P+A group (92.06% vs.79.37%) , P＝0.042. Compared with before treatment ,after 12-week treatment , there were significant reductions in levels of SBP ,DBP ,plasma ET-1 and vWF ,and significant rise in plasma NO level in two groups ;significant rise in serum CysC level in V+A group , P＝0.001 all.Compared with P+A group after 12-week treatment ,there were significant reductions in levels of DBP [(85.34 ± 6.27)mmHg vs.(80.25 ± 6.31)mmHg] ,SBP [(130.33 ± 10.18)mmHg vs.(125.61 ± 10.25)mmHg] ,plasma ET-1 [(63.48 ± 9.30)pg/ml vs.(54.32 ± 9.21) pg/ml] , vWF [(125.78 ± 13.37)% vs.(113.54 ± 13.26)% ] and serum CysC [(1.41 ± 0.31)mg/L vs.(0.89 ± 0.25)mg/L] ,and significant rise in plasma NO level [(75.48 ± 10.65) μmol/L vs.(82.94 ± 10.56)μmol/L] in V+A group ,P＜0.05 or ＜0.01. There was no significant difference in incidence rate of adverse reactions between two groups , P＝0.143. Conclu-sion :Valsartan and perindopril respectively combined amlodipine can effectively reduce blood pressure level in hypertensive patients ,but the former can more significantly improve vascular endothelial function with better therapeutic effect .